Path molecular

Question 1

MED12 mutation

Answer 1

leiomyoma and leiomyosarcoma

Question 2

endometrial tp53 mutation

Answer 2

-type 2 EM Ca (serous)

Question 3

PTEN mutation

Answer 3

-Endometrial hyperplasia –> Type 1 endometrial ca

-

Question 4

MMR/mlh1 gene defect

Answer 4

type 1 EM Ca

Question 5

HMGIC and HMGIY (ch12 and ch6)

Answer 5

leiomyoma

Question 6

KRAS

Answer 6

• low grade serous tumors of the ovary
• mucinous tumors of the ovary
• endometrial hyperplasia: nonatypical –> atypical

Question 7

KOH test

Answer 7

• vulvovaginal candidiasis

- Trichomonas whiff test

Question 8

NAATs (amplified nucleic acid tests)

Answer 8

chlamydia trichomatis

Question 9

HPV 6 and 11

Answer 9

(vulvar) condyloma acuminatum

Question 10

HPV 16 and 18

Answer 10

• Vulvar-IN –> (vulvar) basaloid and warty carcinomas
• Vaginal-IN –>SCCa vagina
• Cervical Ca

Question 11

PAS(Alcian blue stain) +, cytokeratin 7+, S100-

Answer 11

(vulva) Extramammary Paget Disease

Question 12

p16 over expression bc of increased CD14.

Answer 12

(cervix) SIL (Squamous Intraepithelial Lesion)

Question 13

Ki-67 overexpression is indicative of what activity and is the marker of what?

Answer 13

Indicates high mitotic activity (brown stain). Marker for SIL

Question 14

uterine TP53

Answer 14

Type 2 uterine endometrial Ca

Question 15

Normal function of PTEN

Answer 15

Inactivation of PI3K, stopping PI3K from enhancing estrogen receptors and increasing expression at gene targets, stopping overgrowth of estrogen dependent cells.

Question 16

Increased PI3K/AKT results in?

Answer 16

increased estrogen receptor activation

Question 17

PI3K, TP53, PTEN

Answer 17

Malignant mixed mullerian tumors (uterine endometrial)

Question 18

JAZF1 and SUZ12 translocation/fusion(?)

Answer 18

Low grade uterine endometrial stromal sarcoma

Question 19

HMGIC (12q14) and HMGIY (6p); MED12 mutation

Answer 19

leiomyoma

Question 20

KRAS, BRAF, ERBB2

Answer 20

Low grade serous borderline epithelial ovarian tumor

Question 21

TP53, BRCA1/2

Answer 21

High grade serous Ca (Epithelial)

Question 22

KRAS (ovarian)

Answer 22

mucinous tumors of the ovary

Question 23

serum marker CA-125

Answer 23

Monotors expected recurrence and progression of ovarian Ca

Question 24

alpha feto protein

Answer 24

yolk sac ovarian tumor

Question 25

B-hCG elevation

Answer 25

- Germ Cell Choriocarcinoma (malignant, fatal) - Gestational Choriocarcinoma (malignant, curable) - Complete/partial mole

Question 26

inhibin - serum marker for... and function

Answer 26

- Marker for granulosa cell ovarian tumor | - Function: inhibits FSH

Question 27

FOX 2 mutation

Answer 27

adult type granulosa cell ovarian tumor (sex cord stromal tumor)

Question 28

50% of ____ have DICER1 mutation

Answer 28

Sertoli-Leydig Cell Tumor (ovarian)

Question 29

sFlt1 and sENG

Answer 29

Angiogenic factors released from placenta as a result of hypoxia, involved in PREECLAMPSIA.

Question 30

Function of sFlt1

Answer 30

Antagonizes VEGF - decreases maternal/placental angiogenesis in PREECLAMPSIA.

Question 31

Function of sENG

Answer 31

Inhibits TGF-B, decreasing endothelial proliferation fo NO, resutling in systemic vasoconstriction, HTN, hypoperfusion in PREECLAMPSIA.

Question 32

hPL

Answer 32

Placental Site Trophoblastic Tumor